Track Eterna Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Eterna Therapeutics Inc. Common Stock ERNA Open Eterna Therapeutics Inc. Common Stock in new tab

12.25 USD
P/E
0.01
EPS
1214.25
P/B
44.54
ROE
-2505.61
Beta
6.85
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 20, 2026
P/E0.01
EPS1214.25
Book Value0.31
Price to Book44.54
Debt/Equity5.67
% Insiders41.779%
Estimates
Forward P/E-1.42
Forward EPS-9.60

DCF Valuation

Tweak assumptions to recompute fair value for Eterna Therapeutics Inc. Common Stock (ERNA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Eterna Therapeutics Inc. Common Stock Logo Eterna Therapeutics Inc. Common Stock Analysis (ERNA)

United States Health Care Official Website Stock

Is Eterna Therapeutics Inc. Common Stock a good investment? Eterna Therapeutics Inc. Common Stock (ERNA) is currently trading at 12.25 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.01. This relatively low multiple may signal that Eterna Therapeutics Inc. Common Stock is undervalued compared to historical market norms.

Earnings Schedule: Eterna Therapeutics Inc. Common Stock is expected to release its next earnings report on May 20, 2026. The market consensus estimate for Forward EPS is -9.60.

Investor FAQ

Does Eterna Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Eterna Therapeutics Inc. Common Stock?

Eterna Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 20, 2026. The company currently has a trailing EPS of 1214.25.

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) ERNA

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
June 17, 2016 0.020000
March 26, 2021 0.500000
Oct. 17, 2022 0.050000
June 12, 2025 0.066667
May 4, 2026 0.040000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion